Menu

An expert resource for medical professionals
Provided FREE as a service to women’s health

The Alliance for
Global Women’s Medicine
A worldwide fellowship of health professionals working together to
promote, advocate for and enhance the Welfare of Women everywhere

An Educational Platform for FIGO

The Global Library of Women’s Medicine
Clinical guidance and resourses

A vast range of expert online resources. A FREE and entirely CHARITABLE site to support women’s healthcare professionals

The Global Academy of Women’s Medicine
Teaching, research and Diplomates Association

Contraception. 2015 Jun 8. pii: S0010-7824(15)00229

Comparison of remote and in-clinic follow-up after methotrexate/misoprostol abortion

Dunn S, Panjwani D, Gupta M, Meaney C, Morgan R and Feuerstein E

Abstract

Objectives: This study compared adherence to follow-up and clinical outcomes between standard in-clinic and remote follow-up after methotrexate/misoprostol abortion.

Study design: This non-randomized trial recruited women requesting medical abortion at two sexual health clinics in Toronto, Canada. Women received methotrexate 50 mg/m2 followed 3–7 days later by 800 mcg of misoprostol self-administered vaginally. For day 15 follow-up participants could choose standard in-clinic follow-up with ultrasound and assessment, or remote telephone follow-up with serum ßhCG performed at a community laboratory and symptom check-list. Standard and remote follow-up groups were compared for adherence, defined as completing follow-up within 7 days of the scheduled time, and clinical outcomes. Characteristics associated with adherence were assessed using multivariable logistic regression.

Results: Eighty-six (67%) of 129 women chose remote follow-up. Non-adherence rates for remote (28%) and standard (23%) follow-up groups did not differ in univariate (p=0.57) or multivariable analysis (OR 1.09, 95% confidence interval 0.39-3.01). Rates of emergency/hospital visits were 3% and 9% for remote and standard groups respectively (p=0.22) and complete loss to follow was 6% and 14% in remote and standard groups (p=0.18). Non-adherent women were more likely to be undecided about their contraception (65% vs. 28%; p=0.002), and this difference persisted in the multivariable analysis.

Conclusion: Given a choice of remote or in-clinic follow-up after methotrexate/misoprostol abortion, most women chose remote follow-up. Rates of adherence to follow-up, adverse outcomes and complete loss to follow-up were similar for women choosing remote and standard follow-up.

Implications statement: Since standard and remote follow-up after methotrexate/misoprostol abortion are associated with similar adherence to follow-up and similar safety profiles, women should be offered their choice of follow-up method.